Ignyta Announces Pricing Of Public Offering Of Common Stock

Ignyta anticipates using the net proceeds from the offering to fund R&D activities for its development programs, including the clinical development and pre-commercialization activities of entrectinib, and ongoing development of other pipeline assets.